Diabetic Retinopathy Market Size, Share, Growth Analysis, By Type(Proliferative Diabetic Retinopathy, and Non-proliferative diabetic retinopathy), By Management(Anti-VEGF, Intraocular Steroid Injection, Laser Surgery, and Vitrectomy), By Region - Industry Forecast 2024-2031

To increase their market position, major players are focused on collaborations, partnerships, acquisitions, and other strategic operations. Industry leaders face growing competition with novel medication launches and regulatory approval of innovative management treatments, making it challenging for them to remain competitive in an ever-changing industry. However, market leaders' large investments in R&D are predicted to enhance market growth.

Eyenuk, a worldwide artificial intelligence (AI) healthcare company as well as the market leader in practical applications for AI Eye Evaluation and AI Predictive Biomarkers, will be able to market its EyeArt AI retinal screening device throughout the European Union in January 2023 for new uses such as identifying AMD (age-related macular degeneration) and glaucomatous damage to the optic nerve (a sign of glaucoma).

Top Player’s Company Profiles in Diabetic Retinopathy Market

• Novartis AG

• Roche Holding AG

• Bayer AG

• Regeneron Pharmaceuticals, Inc.

• Allergan plc (AbbVie Inc.)

• Carl Zeiss Meditec AG

• Topcon Corporation

• Nidek Co., Ltd.

• Optos plc (Nikon Corporation)

• Bausch Health Companies Inc.

• Alcon Inc.

• Santen Pharmaceutical Co., Ltd.

• Lumenis Ltd. (XIO Group)

• Iridex Corporation

• Leica Microsystems (Danaher Corporation)

• StemCells Inc. (Microbot Medical Inc.)

• Bioptigen, Inc. (Metabolic Technologies Inc.)

• CenterVue SpA

• Visunex Medical Systems, Inc.

• Clarity Medical Systems, Inc.

Diabetic Retinopathy Market